ADG 206
Alternative Names: ADG-206Latest Information Update: 28 Feb 2023
At a glance
- Originator Adagene
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Feb 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT05614258)
- 30 Aug 2022 Adagene plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in Australia, in early 2023
- 30 Aug 2022 Adagene submits regulatory filing with the Human Research Ethics Committee for a phase I clinical trial in Australia